Drug intelligence / Profile preview

SHD033

Development stage: Unknown
Lead developer: Shihuida Pharmaceutical Group
Administration: Topical

Overview

SHD033 is an investigational biological therapeutic being developed by Shihuida Pharmaceutical Group for the treatment of dermatological conditions. It is designed for topical administration, specifically described in pipeline documentation as a liquid or water-based preparation (皮性制剂水). As of early 2024, the drug is in Phase 1 clinical development. Detailed information regarding its specific molecular target, mechanism of action, or the specific skin diseases it is intended to treat has not been publicly disclosed by the developer.

Beyond the preview

Go deeper on SHD033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHD033.

Explore the full profile